1. Generics Bulletin
  2. >>Policy & Regulation

Unsealed Price-Fixing Complaint Reveals Emails

 
• By Dave Wallace

Emails between major generics firms including Teva, Sandoz and Mylan have been revealed after a court unsealed a complaint filed by 44 US states claiming widespread price-fixing among numerous industry players.

Message
Emails between major generics firms have been revealed in an unsealed US price-fixing lawsuit • Source: Shutterstock

A series of emails between generics firms published as part of an unredacted lawsuit alleging widespread price-fixing in the US generics industry reveals “brazen co-ordination to artificially inflate prices, hinder competition and unreasonably restrain trade across the industry,” according to Connecticut attorney general William Tong.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.